AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights

https://www.businesswire.com/news/home/20180809005208/en/AmpliPhi-Biosciences-Reports-Quarter-2018-Financial-Results

  • 19 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have been treated with AB-SA01 or AB-PA01 under single-patient expanded access program

  • AmpliPhi has scheduled meetings with the FDA in August and September to discuss the regulatory path forward for AB-SA01 and AB-PA01

Unknown's avatar

Published by Dr. Prasanth Manohar, Ph.D.,

Early career researcher in the field of Microbiology. Phage biologist, Author, Editor and Scientific writer. Expertise is in bacteriophage biology & genetics, Phage Therapy, ssRNA phages, Phage lysis systems, Single-cell analysis, protein antibiotics, and Antibiotic Resistance.